TTOO

Analyst Sentiment

Wall St. Consensus
Hold
10 analysts·Moderate coverage
57
Score
3 Buy (30%)6 Hold (60%)1 Sell (10%)
Rating Breakdown
Strong Buy
110%
Buy
220%
Hold
660%
Sell
110%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$5.00
+1249900.0%
Consensus
$5.00
+1249900.0%
Bull
$5.00
+1249900.0%
12-Month Target Range10 analysts
$5.00$5.00$5.00
Current $0.00Consensus
Current Price
$0.00
Upside to Consensus
$5.00

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+37.24%
EPS
FY2028
Rev+32.17%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028E
Revenue Avg$33M$46M$60M
Low$33M$46M$60M
High$33M$46M$60M
EBITDA Avg$5M$6M$7M
Low$5M$6M$7M
High$5M$6M$7M
EBIT Avg$5M$5M$6M
Low$5M$5M$6M
High$5M$5M$6M
Net Income Avg$-2M$-1M$-782,995
Low$-2M$-1M$-782,995
High$-2M$-1M$-782,995
EPS Avg$-0.70$-0.46$-0.30
Low$-0.70$-0.46$-0.30
High$-0.70$-0.46$-0.30
Analysts (Rev / EPS)1 / 11 / 11 / 1

Earnings Surprises

Recent Analyst Actions

Jul 30, 2024Canaccord Genuity
T2 Biosystems, Inc (TTOO) PT Raised to $5 at Canaccord Genuity
Target:$5.00
+5.5%from $4.74
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.